OCD
64 programs · 63 companies
Programs
64
Companies
63
Trials
65
MOAs
41
PRMT5iCD3xCD20EZH2iHER2CFTRmodBTKiSTINGagBiTEALKiIL-17i
Drugs
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| RHH-682 | Phase 2 | FXIa | ||
| Zanuderotide | Phase 1/2 | VEGF | ||
| NVO-9615 | Phase 2/3 | PRMT5 | ||
| TAK-9344 | Phase 3 | CGRP | ||
| Darafutibatinib | Preclinical | PRMT5 | ||
| BMR-8377 | Phase 1/2 | PCSK9 | ||
| INC-5849 | Phase 2 | PCSK9 | ||
| Geliglumide | Phase 1 | Aβ | ||
| RCU-6379 | Phase 1/2 | DLL3 | ||
| Nidasacituzumab | Phase 3 | TIGIT | ||
| Sovaglumide | Phase 3 | PCSK9 | ||
| 600-1765 | Approved | B7-H3 | ||
| Doxafutibatinib | Phase 1 | BET | ||
| SWO-IIT-447 | Approved | CD47 | ||
| Tirasacituzumab | NDA/BLA | BET | ||
| XTA-1681 | NDA/BLA | AuroraA | ||
| Nirainavolisib | Phase 3 | IL-13 | ||
| CRG-4097 | Phase 3 | TIGIT | ||
| CLL-8422 | Approved | KRASG12C | ||
| REP-2935 | Approved | CD20 | ||
| Doxalucimab | Phase 1/2 | BET | ||
| UPB-4925 | Phase 2/3 | KRASG12D | ||
| Doxarapivir | Phase 2 | EGFR | ||
| Olpasertib | Phase 3 | DLL3 | ||
| Zorifotisoran | Preclinical | IL-23 | ||
| NBY-4130 | Phase 3 | IL-17A | ||
| Nidasertib | Approved | CD38 | ||
| Nirarasimod | Phase 1/2 | MDM2 | ||
| NGM-3123 | Phase 3 | FcRn | ||
| Mirirelsin | Preclinical | BCL-2 | ||
| Kemafotisoran | Phase 3 | MALT1 | ||
| BIO-9035 | Phase 2/3 | MDM2 | ||
| COR-2320 | Preclinical | WEE1 | ||
| 151-9555 | Phase 2/3 | B7-H3 | ||
| BIO-7835 | Phase 1/2 | USP1 | ||
| Tirazanubrutinib | Phase 3 | FGFR | ||
| CHR-9224 | Phase 2 | Cl18.2 | ||
| CEL-1794 | Approved | PARP | ||
| ORC-9172 | Phase 3 | C5 | ||
| TUR-6841 | Phase 1 | RET | ||
| Gozederotide | NDA/BLA | WEE1 | ||
| Semacagene | Phase 1/2 | SGLT2 | ||
| Tixatuximab | Phase 3 | PRMT5 | ||
| Nidalemzoparlimab | Phase 1 | SOS1 | ||
| Tixaratamab | Preclinical | Tau | ||
| 174-8981 | Phase 2 | Aβ | ||
| Rimavorutinib | Phase 1 | RET | ||
| NAN-6418 | Phase 2 | BCMA | ||
| BER-6094 | Phase 3 | CDK2 | ||
| FER-2526 | NDA/BLA | CD47 | ||
| Elracapivasertib | Phase 1/2 | TIM-3 | ||
| MIR-8412 | Phase 1/2 | APOC3 | ||
| JUB-6215 | Phase 2/3 | CD20 | ||
| Tiraderotide | Phase 2 | BTK | ||
| THA-9190 | Preclinical | WEE1 | ||
| Polalemzoparlimab | Approved | GPRC5D | ||
| RUI-IIT-202 | Phase 1 | WEE1 | ||
| NAT-IIT-589 | Phase 1/2 | CDK4/6 | ||
| RAB-IIT-774 | Phase 2 | GIP-R | ||
| 600-5291 | Phase 2 | LAG-3 | ||
| Datozanubrutinib | NDA/BLA | PRMT5 | ||
| ZEN-2386 | Phase 3 | PCSK9 | ||
| Fixatinib | Phase 1/2 | IL-17A | ||
| ZHE-740 | Approved | JAK2 |
Trials (65)
| NCT | Drug | Phase | Status |
|---|---|---|---|
| NCT07558107 | RHH-682 | Phase 2 | Not yet recr... |
| NCT06397573 | RHH-682 | Phase 2 | Terminated |
| NCT05026679 | Zanuderotide | Phase 1/2 | Terminated |
| NCT03648944 | TAK-9344 | Phase 3 | Recruiting |
| NCT03654689 | TAK-9344 | Phase 3 | Not yet recr... |
| NCT06633066 | Darafutibatinib | Preclinical | Active |
| NCT05483491 | BMR-8377 | Phase 1/2 | Completed |
| NCT04372386 | RCU-6379 | Phase 1/2 | Not yet recr... |
| NCT03256451 | RCU-6379 | Phase 1/2 | Active |
| NCT08812722 | Nidasacituzumab | Phase 3 | Terminated |
| NCT08956838 | Sovaglumide | Phase 3 | Terminated |
| NCT05781860 | Sovaglumide | Phase 3 | Recruiting |
| NCT05223842 | 600-1765 | Approved | Active |
| NCT05138539 | SWO-IIT-447 | Approved | Not yet recr... |
| NCT08366114 | Tirasacituzumab | NDA/BLA | Completed |
| NCT05674237 | Nirainavolisib | Phase 3 | Terminated |
| NCT04800534 | Nirainavolisib | Phase 3 | Active |
| NCT07819705 | CLL-8422 | Approved | Terminated |
| NCT08966780 | CLL-8422 | Approved | Active |
| NCT05689347 | REP-2935 | Approved | Completed |